Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System.

María Elena Cabrera,Camila Peña,Pilar Leon,Vivianne Lois,Hernán Rojas, Valeska Vega,Alvaro Pizarro,Susana Calderon,Christine Rojas,Augusto Aspillaga, M Luisa Gonzalez,Marvila Intriago,Bernardita Rojas, Cecilia Hales, Jacqueline Oliva,Mónica Romero, Marisa Capurro,Jorge J Castillo

JCO global oncology（2022）

引用 1|浏览11

暂无评分

摘要

Rituximab improved the survival of patients with DLBCL diagnosed and treated in Chile. The benefit was sustained over time, with curative rates of > 50%. This intervention shows that the inclusion of this biological drug justified the expenses incurred by the Ministry of Health in the National Lymphoma Protocols in Chile.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要